Donecopride targets amyloid aggregation, resulting in neuroprotection, but also hyperphosphorylation of the TAU protein, a second major biomarker of Alzheimer’s disease, and finally performs a neurotrophic action leading to synaptogenesis. Here, MAPT is linked to Alzheimer disease.